Heart Disease News and Research

Latest Heart Disease News and Research

Biogen Idec and Cardiokine terminate lixivaptan collaboration

Biogen Idec and Cardiokine, Inc. today announced that they have agreed to dissolve their collaboration on lixivaptan. The termination of the collaboration, which began in 2007, triggers the return of all rights to lixivaptan to Cardiokine.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Regulus receives $488,989 grant under QTDP program

Regulus Therapeutics Inc. announced today that it has been awarded two grants totaling $488,989 under the Federal government's Qualifying Therapeutic Discovery Project Program.

4 Nov 2010

New simple blood test may help diagnose Niemann-Pick type C disease

A fatal genetic disorder that frequently takes years to diagnose may soon be detectable with a simple blood test, researchers at Washington University School of Medicine in St. Louis and the National Institutes of Health (NIH) report this week in Simple blood test may diagnose deadly Niemann-Pick type C disease.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

One-third of breast cancer survivors rate breast-conserving treatments as fair

A third of breast cancer survivors who received the breast-conserving treatments lumpectomy and radiation rate the appearance of their post-treatment breast as only "fair" or "poor" in comparison to their untreated breast, according to a new University of Pennsylvania School of Medicine study that will be presented today at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.

3 Nov 2010

BioClinica third quarter service revenues increase to $15.8 million

BioClinica®, Inc., a global provider of clinical trial management services, today announced its financial results for the three and nine months ended September 30, 2010.

From Clario 3 Nov 2010

Cambridge Heart third quarter sales increase 21% to $793,000

Cambridge Heart, Inc., today reported results for the three and nine months ended September 30, 2010.

3 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.

3 Nov 2010

IDEV receives FDA marketing clearance for SUPERA VERITAS Transhepatic Biliary System

IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance to market the SUPERA VERITAS Transhepatic Biliary System.

3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

MiCardia receives European CE Mark approval for enCor Mitral Valve Repair System

MiCardia Corporation announced today that it has received the CE Mark to begin marketing the Company's enCor™ Mitral Valve Repair System in the European Union.

3 Nov 2010

Lifestyle changes and natural supplements can control blood sugar levels

The holiday season can make it challenging for people with diabetes to keep their blood sugar levels stable. Diabetes expert, Dr. Isaac Eliaz recommends prevention through a number of lifestyle changes and natural supplements.

3 Nov 2010

Effort exerted on cognitive task influenced by masked action or inaction cues

People may have a better memory for birthdays that are closer to their own: Volunteers recalling their friends' birthdays tended to remember birthdays that were closer to their own than birthdays that were farther away from their own birthday.

3 Nov 2010

Health Affairs recognizes U-M leadership in implementing Value-Based Insurance Design

Value-Based Insurance Design - a concept created at the University of Michigan and incorporated in the nation's new health care reform law - is the focus of an upcoming national policy journal.

3 Nov 2010

Electrophysiology Innovations Congress EP Innovations 2010 to highlight treatment of atrial fibrillation

The North American Center for Continuing Medical Education, LLC , in partnership with HMP Communications, LLC, publisher of EP Lab Digest, today announced several key sessions on the treatment of atrial fibrillation at the upcoming Electrophysiology Innovations Congress EP Innovations 2010, the world's premier annual electrophysiology meeting, to be held December 9-11, 2010, at the Washington Hilton in Washington, DC.

3 Nov 2010

Cardiovascular Systems enters settlement agreement with ev3

Cardiovascular Systems, Inc. announced today that it has entered into a settlement agreement with ev3, Inc., now part of Covidien plc. The agreement dismisses all claims and counterclaims in the employment lawsuit between the two companies. The litigation stems from a suit ev3 originally filed against CSI in 2007 related to employees who joined CSI from ev3.

3 Nov 2010

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that three of the Company's therapeutic development programs, VIMOVO (naproxen / esomeprazole magnesium) (formerly PN400), PA32540 and PA65020, qualified to receive federal grant funding under The Patient Protection and Affordable Care Act.

3 Nov 2010

Study suggests heredity may play a role in determining infant's susceptibility to AOP

A potentially life-threatening challenge characterized by pauses in breathing that can last for more than 20 seconds, apnea of prematurity (AOP) affects more than 50 percent of premature infants and is almost universal in the smallest of preemies. Caused in part by an underdeveloped central nervous system that can't adequately regulate breathing outside of the womb, especially during sleep, AOP is not yet fully understood by scientists and remains a grave concern among neonatologists and parents alike.

3 Nov 2010